Title: Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation

Short title: COVID-19 Infection and Stroke

Jintong Liu, BS<sup>1</sup>, Eric Fu, MS<sup>1</sup>, Riley Gillette, MPH<sup>1</sup>, Max Wohlauer, MD<sup>1\*</sup>

<sup>1</sup>University of Colorado School of Medicine,

 $*Correspondence: \underline{max.wohlauer@cuanschutz.edu} \\$ 

12631 E. 17<sup>th</sup> Avenue, Room 5411

Aurora, CO 80045

Total Word Count: 4281

### 1 Abstract

### 2 Background

COVID-19 infection is associated with thrombotic events; however, this phenomenon is poorly
understood. Few studies have reported the association between COVID-19 and stroke in the
hospital setting.

6

### 7 Methods

8 We retrospectively reviewed and characterized all patients who presented to a single, quaternary 9 medical center between March and December 2020 (N=603). COVID-19 positive patients who 10 developed ischemic or hemorrhagic stroke were included in the analysis (N=66). This cohort was 11 compared with patients who were COVID-19 negative at the time of stroke presentation in the 12 same period (N=537). Statistical significance was evaluated using Pearson's Chi squared test 13 with Yates' continuity correction and linear model ANOVA.

14

### 15 **Results**

Sixty-six patients had COVID-19 and Stroke. Of these patients, 22 (33.4%) patients initially presented with stroke and 44 (66.7%) initially presented with COVID-19. Patients who presented with COVID-19 and had a stroke during their hospitalization (COVID-first) had worse outcomes than patients presenting to the hospital with stroke whose COVID test became positive later in the hospitalization (stroke-first). Patients who presented with COVID-19 and had a stroke during their hospitalization had an increased rate of acute renal failure (48.9% vs 19.0%, p=0.021) and need for ventilation (60.0% vs 28.6%, p=0.017). Further, in the COVID-first cohort, the use of

23	heparin prior to the stroke event was not associated with mortality or type of stroke (ischemic or
24	hemorrhagic).

## 26 Conclusion

- 27 In the early pandemic, patients with COVID-19 infection and stroke had a higher mortality rate
- compared to COVID-19 negative patients with stroke. Among patients with both COVID-19 and
- stroke, patients presenting with COVID-19 first had worse outcomes than patients presenting
- 30 with stroke first. The use of heparin prior to the stroke event was not associated with mortality or
- 31 type of stroke.
- 32
- 33 Key words:
- 34 COVID-19
- 35 Stroke
- 36
- 37 Non-standard Abbreviations and Acronyms
- 38 chronic kidney disease (CKD)
- 39 angiotensin-converting enzyme 2 (ACE2)
- 40
- 41
- 42
- 43
- 44
- 45

### 46 Introduction

Over 6.9 million people have died from COVID-19 worldwide and hundreds of millions more
have suffered from SARS-CoV-2 associated illness. <sup>1</sup> While most symptoms involve the
respiratory tract, neurologic symptoms such as altered consciousness, seizures, stroke, and
sensory deficits have been extensively described. <sup>2</sup> Stroke incidence in COVID-19 patients
ranges between 0.1 to 6.9% of hospitalized cases. <sup>3,4</sup>

52

COVID-19 is associated with a hypercoagulable state and resulting thromboembolic events, 53 including deep vein thrombosis, pulmonary embolism, and stroke.<sup>4-7</sup> Several mechanisms have 54 55 been proposed including endothelial injury, inflammation, complement activation, and deactivation of antithrombotic pathways. <sup>8</sup>An interesting model, based off postmortem studies 56 and these mechanisms, postulates that injury to the lung tri-compartment (pulmonary artery, 57 bronchial artery, and alveolus) leads to pulmonary vein thrombosis and subsequent large vessel 58 occlusion (LVO)<sup>9</sup>. In terms of demographics, COVID-19 patients who suffered strokes are also 59 demographically different from traditional stroke patients. They are typically younger, more 60 often without previous vascular risk factors, more likely to be male, and more likely to 61 experience large vessel occlusions. <sup>3,5,10</sup> 62

63

Despite the large number of studies on stroke and COVID-19 that have been published, a causal relationship between SARS-CoV-2 and stroke has yet to be established. <sup>3</sup> Moreover, there is a notable gap in research concerning hemorrhagic stroke within the context of SARS-CoV-2 infection, despite documented instances of hemorrhagic complications. <sup>4,5</sup> In addition to reporting occurrence and outcome, one way to explore possible correlations is by differentiating the

chronologic sequence of the presenting symptoms. Our study separates stroke patient outcomes
through patients' primary presentation, whether they presented with COVID-19 or stroke first.
Furthermore, we explored the relationship between timing of anticoagulation on outcomes,
which has not been described previously.

73

### 74 Methods

75 We conducted a retrospective study of 603 consecutive patients who presented with stroke in a quaternary medical center between March 2020 and December 2020. Sixty-six patients who 76 77 were COVID-19 positive and 537 patients who were COVID-19 negative at the time of ischemic 78 or hemorrhagic stroke presentation were included. Characteristics and comorbidities were 79 identified and compared between two groups using Pearson's Chi squared test with Yates' continuity correction and linear model ANOVA. Missing data such as race and sex were not 80 included in analysis. Comparisons stratified by stroke types (ischemic or hemorrhagic) and 81 82 mortality rates were also performed. Within the 66 patients who were COVID-19 positive at the time of ischemic or hemorrhagic stroke presentation, we further stratified by their primary 83 presentation, whether patients presented with COVID-19 first and developed a stroke during 84 85 their hospitalization (N=45) (stroke-first) or whether stroke was the initial presenting symptom 86 of COVID-19 (COVID-first) (N=21). Characteristics, comorbidities, and outcomes were 87 compared between two groups. A multivariable logistic regression model was used with the 88 presence or absence of postoperative death as the dependent variable, COVID-19 and stroke 89 presentation, and comorbidities diabetes mellitus and chronic kidney disease (CKD) as 90 independent variables based off significance in univariate analyses. In addition, we identified 91 causes of death by systems for those who were COVID-19 positive at the time of stroke

92	presentation. Lastly, for the COVID-first cohort (N=45), we distinguished those who received
93	prophylaxis or therapeutic heparin from those who did not prior to the onset of stroke. The types
94	of stroke and mortality rate were then compared with Pearson's Chi-squared test with Yates'
95	continuity correction. Statistical significance was defined as $p < 0.05$ . Analyses were done using
96	R (version 4.2.0, R Foundation for Statistical Computing, Vienna, Austria).
97	
98	The case report form was developed by a working group of the Vascular Surgery COVID-19
99	Collaborative (VASCC). <sup>11</sup> The VASCC was established on March 2, 2020, to study the impact

100 of the ongoing COVID-19 pandemic on vascular surgical care. STROBE guidelines for

101 observational studies were followed.

102

### 103 **Results**

104 The mean age for all patients was 64.4 years old, and it was similar between both cohorts (Table 105 1). More patients identified as Hispanic in the COVID & Stroke cohort than patients in the 106 Stroke Only cohort (40.9% vs 11.4%, p<0.001). The male and female distribution was similar 107 between the two cohorts (p=0.200). Prevalence of diabetes mellitus and chronic kidney disease 108 were higher in the COVID & Stroke cohort than in the Stroke Only cohort (p<0.001). Ischemic 109 stroke was more prevalent than hemorrhagic stroke in all patients and in both cohorts. Mortality 110 was significantly higher in the COVID & Stroke cohort (patients with COVID who developed a 111 stroke) than in the Stroke Only cohort (37.9% vs 17.3%, p<0.001). 112

113 Stratified based on the stroke type (hemorrhagic or ischemic), similar results were found

114 (Supplemental Tables 1 and 2). However, for patients presented with hemorrhagic stroke, the

115	mortality rates were not statistically significant between the COVID & Stroke cohort and the
116	Stroke Only cohort (40.9% vs 26.4%, p=0.249). When modeled in a multivariable logistic
117	regression framework, Stroke and COVID-19 presentation (OR: 0.41, 95% C.I. (0.23, 0.73),
118	p=0.002) and CKD (2.36, (1.12-4.82), $p = 0.02$ ) were significantly associated with postoperative
119	death, diabetes mellitus did not have a significant association (1.15, (0.73,1.79), p=0.528).
120	Patients who presented with stroke only were less likely to experience postoperative death
121	compared to those with both stroke and COVID-19. Patients with CKD were more likely to
122	experience postoperative death compared to non-CKD patients. In terms of revascularization, out
123	of 44 patients with ischemic stroke and COVID-19, only one patient received mechanical
124	thrombectomy and only three patients received IV thrombolysis (2.3% and 6.8% respectively).
125	
126	When stratified by primary presentation (COVID or Stroke) within the COVID & Stroke cohort,
127	demographic characteristics and comorbidities were not significantly different between the two
128	
120	groups (Table 2). Type of strokes and mortality rates were also not significantly different
129	
	groups (Table 2). Type of strokes and mortality rates were also not significantly different
129	groups (Table 2). Type of strokes and mortality rates were also not significantly different between two groups. Patients with COVID-19 as the primary presentation were associated with
129 130	groups (Table 2). Type of strokes and mortality rates were also not significantly different between two groups. Patients with COVID-19 as the primary presentation were associated with worse outcomes including increased acute renal failure and need for ventilation rates when
129 130 131	groups (Table 2). Type of strokes and mortality rates were also not significantly different between two groups. Patients with COVID-19 as the primary presentation were associated with worse outcomes including increased acute renal failure and need for ventilation rates when compared to patients presented with stroke first (48.9% versus 19.0%, p=0.021 and 60.0% versus
129 130 131 132	groups (Table 2). Type of strokes and mortality rates were also not significantly different between two groups. Patients with COVID-19 as the primary presentation were associated with worse outcomes including increased acute renal failure and need for ventilation rates when compared to patients presented with stroke first (48.9% versus 19.0%, p=0.021 and 60.0% versus

136 causes of death were most common, followed by pulmonary causes.

138	In the COVID-first cohort (N=45), the use of heparin prior to the stroke event was not associated
139	with type of stroke or mortality (Table 4). Among the 29 patients who received heparin, 13
140	developed hemorrhagic stroke, and 16 developed ischemic stroke, which was not significantly
141	different from those who did not receive heparin (p=0.321). Mortality rate was 41.4% in those
142	who received heparin while 37.5% in those who did not receive heparin (p=1.000).
143	

# 144 **Discussion**

In this retrospective cohort study, we found significant differences in the demographics of the cohort who had a stroke versus those who had both a stroke and COVID-19 in terms of the presence of diabetes, CKD, and race. We also found a significant difference in mortality and morbidity. Additionally, we looked specifically at those with hemorrhagic stroke, as opposed to ischemic stroke, and did not find a correlation with heparin use in our cohort in contrast to previous studies.

151

### 152 Stroke Overall

In terms of both ischemic and hemorrhagic stroke, our key findings include a greater prevalence
of diabetes, CKD, and Hispanic ethnicity in those with COVID-19 infection and stroke than
those with only a stroke, higher mortality in those with both, and worse outcomes for those
presented with COVID-19 first then stroke as opposed to stroke first then COVID-19.

157

158 It has been widely observed that diabetes and CKD are both risk factors associated with

increased COVID-19 infection rates and the severity. <sup>12,13</sup> For our cohort, diabetes mellitus (27%

160 vs 56%, p<0.001) and CKD (4.5% vs 20%, p<0.001) were both significantly more prevalent in

those who had COVID and stroke than those who presented only with stroke. Not only are
patients with these comorbidities more likely to be infected by SARS-CoV2, but they could also
be more likely to suffer stroke while infected.

164

Additionally, there is a significant difference in the racial makeup of those who suffered only a stroke (n=537) versus those who had both COVID-19 and stroke (n=66, p<0.001). This contrasts with no significant difference found between those who had COVID-19 first then stroke versus having stroke first then COVID-19. This significant difference aligns with general COVID-19 trends where the infection disproportionally affects those in the minority. <sup>14</sup> We observed that those who identify as Hispanic were a significantly greater percentage of the overall COVID-19 and stroke patient population than stroke only (41% vs 13%).

172

173 In terms of mortality, our findings revealed that those with COVID-19 and stroke during the 174 same hospital stay exhibited a higher death rate than those who suffered from a stroke only (38% vs 17%, p<0.001) in the early stages of pandemic. This builds upon earlier research indicating 175 elevated mortality in COVID-19 patients with stroke compared to those without, <sup>15</sup> as well as an 176 177 increased risk of severe disability and mortality when compared to propensity-matched non-COVID-19 stroke patients.<sup>16,17</sup> Our clinical observations align with this conclusion, suggesting 178 179 that a higher disease burden correlates with increased mortality, particularly in diseases with 180 inherently high mortality rates. Furthermore, even within the same disease, more severe infections were associated with a higher incidence of stroke.<sup>15</sup> 181

183	Interestingly, patients who presented with COVID-19 and had a stroke during their
184	hospitalization (COVID-first) had worse outcomes than patients presenting to the hospital with
185	stroke whose COVID-19 test became positive later in the hospitalization (stroke first). Those
186	who were admitted with symptoms of COVID-19 and endured a stroke during their
187	hospitalization were more likely to have acute renal failure (49% vs 19%, p=0.021) and need
188	ventilation (60% vs 29%, p=0.017). This could reflect the differences in the severity of the
189	COVID-19 infection in the two groups. For patients with stroke first in this study, they were
190	more likely to have an asymptomatic COVID-19 infection that was not severe enough to have
191	been tested. For those with COVID-19 first, they were likely hospitalized with COVID-19
192	pneumonia and needed ventilation and were also more likely to experience acute renal failure, a
193	common morbidity of COVID-19. <sup>18</sup>
10/	

### 195 Hemorrhagic Stroke

Despite COVID-19 being mostly characterized as a hypercoagulable state, bleeding 196 197 complications such as increased morbidity/mortality post-stroke revascularization and hemorrhagic strokes have been reported. <sup>4,6,19</sup> Previous studies found that while inherent risk of 198 hemorrhagic stroke low, overall risk is increased in the setting of full-dose anticoagulation use 199 for thromboembolism prevention as part of COVID-19 management.<sup>20</sup> Thus, our study strived to 200 delineate between ischemic and hemorrhagic stroke, separate outcome by heparin use, and 201 202 compare comorbidities within each type of stroke between those who had stroke only versus those who had both COVID-19 and stroke. 203

205 Among patients with hemorrhagic stroke, hyperlipidemia was more likely in those who had both 206 stroke and COVID-19 than those who only had a stroke (p=0.046). While previous studies found that hyperlipidemia is not significantly associated with all-cause mortality in COVID-19 patients, 207 it in combination with COVID-19 may specifically predispose patients to hemorrhagic stroke.<sup>21</sup> 208 209 Second, in contrast with previous studies, we did not find hemorrhagic stroke to be more 210 common in patients with pre-existing hypertension and diabetes mellitus prior to COVID-19 infection.<sup>22</sup> Third, in the COVID-first cohort (N=45), the use of heparin prior to the stroke event 211 212 showed no significant correlation with mortality (p=1.000) or type of stroke (p=0.321). This 213 outcome is surprising given anticoagulation is a known risk of hemorrhage.<sup>23</sup> When compared to findings from a previous a multinational study, our research revealed a higher prevalence of 214 hemorrhagic strokes (33.3% versus 21.1%).<sup>24</sup> Contrary to expectations, our results suggest that 215 216 the use of heparin prior to a stroke does not seem to contribute to the elevated incidence of 217 hemorrhagic strokes. This intriguing observation prompts the need for further exploration and 218 investigation.

219

Hemorrhagic stroke in patients with COVID-19 has not been heavily studied and mechanisms
are still being elucidated. In combining our findings with those of others, several possible
mechanisms begin to emerge. COVID-19 disproportionately affects those with underlying
hypertension and diabetes and further elevates blood pressure through ACE2 dysregulation and
endothelial dysfunction. <sup>23,25</sup> Furthermore, anticoagulant use has become wide-spread in COVID19 treatment. <sup>23,25</sup> Dysregulated fibrinolysis could be another co-existing or separate mechanism.
<sup>20</sup> As such, patient risk factors should be considered when starting anticoagulation therapy. <sup>20,25</sup>

### 228 Limitations

Our study is limited by data from a single center and the retrospective nature of the study. The study is a snapshot in time, focusing on the 66 patients with both COVID-19 and stroke who presented from during the initial waves of COVID-19 (March to December of 2020) and was prior to the introduction of vaccines. This may limit the generalizability of the study. Second, our examination on heparin-use and its resultant morbidity and mortality was done retrospectively.

234

235 Additionally, our ability to conduct statistical analyses was limited due to the small number of 236 patients undergoing revascularization. Only one out of the 44 patients with ischemic stroke and 237 COVID-19 underwent mechanical thrombectomy, while just three received IV thrombolysis 238 (2.3% and 6.8%, respectively). These figures are notably lower when compared to a previous multinational study, where 7.4% of patients underwent mechanical thrombectomy and 13.6% 239 received IV thrombolysis.<sup>24</sup> The majority of patients in our study faced challenges in receiving 240 241 revascularization, either due to their unstable condition, being outside the optimal 242 revascularization window, or lacking indications for the procedure. Despite the absence of formal analysis in our study, a recent international multicenter retrospective cohort study 243 244 suggested that patients with COVID-19 who underwent revascularization experienced worse outcomes than their counterparts without COVID-19 who underwent similar interventions.<sup>19</sup> 245 246

In summary, our study retrospectively examined patients at a tertiary medical center during the
initial wave of COVID-19 and found several previously less reported trends among stroke
patients. First, patients with COVID-19 infection and stroke had a higher mortality rate than
patients with only stroke. Second, among patients with both COVID-19 and stroke, patients

251	presenting with COVID-19 first had worse outcomes, including higher frequency of acute renal
252	failure and need for ventilation, than patients presenting with stroke first. Third, contrary to
253	previous studies, the use of heparin prior to the stroke event was not associated with mortality or
254	type of stroke.
255	
256	Acknowledgments
257	We would like to thank the Medical Student Summer Research Program (MSRP) and
258	Department of Surgery at the University of Colorado School of Medicine for providing time and
259	support to perform this project. We would like to thank the Division of Neurology at the
260	University of Colorado School of Medicine for their collaboration, and for providing valuable
261	input and expertise.
262	
263	Sources of Funding
264	None.
265	
266	Disclosures
267	No financial conflicts to disclose.
268	
269	
270	
271	
272	

### 274 **References:** 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at 275 Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. 2023. Accessed 276 September 3<sup>rd</sup>. 277 Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications 278 2. 279 associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 280 coronavirus disease 19 (COVID-19). J Neurol. 2021;268:3059-3071. doi: 10.1007/s00415-021-10406-y 281 282 3. Sagris D, Papanikolaou A, Kvernland A, Korompoki E, Frontera JA, Troxel AB, Gavriatopoulou M, Milionis H, Lip GYH, Michel P, et al. COVID-19 and ischemic 283 stroke. Eur J Neurol. 2021;28:3826-3836. doi: 10.1111/ene.15008 284 Mbonde AA, O'Carroll CB, Grill MF, Zhang N, Butterfield R, Demaerschalk BM. Stroke 285 4. Features, Risk Factors, and Pathophysiology in SARS-CoV-2-Infected Patients. Mayo 286 287 Clin Proc Innov Qual Outcomes. 2022;6:156-165. doi: 10.1016/j.mayocpiqo.2022.01.003 5. Luo W, Liu X, Bao K, Huang C. Ischemic stroke associated with COVID-19: a 288 systematic review and meta-analysis. J Neurol. 2022;269:1731-1740. doi: 289 290 10.1007/s00415-021-10837-7 Amiri HA, Razavi AS, Tabrizi N, Cheraghmakani H, Baghbanian SM, Sedaghat-Chaijan 291 6. 292 M, Zarvani A, Ghazaeian M, Hosseinnataj A. The Effects of COVID-19 on Patients with

- Acute Ischemic and Hemorrhagic Stroke. *J Stroke Cerebrovasc Dis*. 2022;31:106512.
- doi: 10.1016/j.jstrokecerebrovasdis.2022.106512

295	7.	Alahyari S, Moradi M, Rajaeinejad M, Jalaeikhoo H. Post-COVID-19 hematologic
296		complications: a systematic review. Expert Rev Hematol. 2022;15:539-546. doi:
297		10.1080/17474086.2022.2080051
298	8.	Shibeeb S, Ahmad MN. Thrombotic and Hypercoagulability Complications of COVID-
299		19: An Update. J Blood Med. 2021;12:785-793. doi: 10.2147/jbm.S316014
300	9.	Meaney JFM, O'Donnell JS, Bridgewood C, Harbison J, McGonagle D. Perspective: The
301		Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within
302		Thrombosed Pulmonary Venules. Stroke. 2022;53:2411-2419. doi:
303		10.1161/strokeaha.121.038056
304	10.	Jabbour P, Dmytriw AA, Sweid A, Piotin M, Bekelis K, Sourour N, Raz E, Linfante I,
305		Dabus G, Kole M, et al. Characteristics of a COVID-19 Cohort With Large Vessel
306		Occlusion: A Multicenter International Study. Neurosurgery. 2022;90:725-733. doi:
307		10.1227/neu.000000000001902
308	11.	Mouawad NJ, Cuff RF, Hultgren R, Chuen J, Galeazzi E, Wohlauer M. The Vascular
309		Surgery COVID-19 Collaborative (VASCC). J Vasc Surg. 2020;72:379-380. doi:
310		10.1016/j.jvs.2020.04.463
311	12.	Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence,

- 312 pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr*.
- 313 2020;14:303-310. doi: 10.1016/j.dsx.2020.04.004
- 314 13. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. *Nat*
- 315 *Rev Nephrol.* 2020;16:705-706. doi: 10.1038/s41581-020-00349-4

316	14.	Golestaneh L, Neugarten J, Fisher M, Billett HH, Gil MR, Johns T, Yunes M, Mokrzycki
317		MH, Coco M, Norris KC, et al. The association of race and COVID-19 mortality.
318		EClinicalMedicine. 2020;25:100455. doi: 10.1016/j.eclinm.2020.100455
319	15.	Ahmad SJ, Feigen CM, Vazquez JP, Kobets AJ, Altschul DJ. Neurological Sequelae of
320		COVID-19. J Integr Neurosci. 2022;21:77. doi: 10.31083/j.jin2103077
321	16.	Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, Calleja P, Ostos F,
322		González-Ortega G, Fuentes B, et al. Characteristics and Outcomes in Patients With
323		COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. Stroke.
324		2020;51:e254-e258. doi: 10.1161/strokeaha.120.031208
325	17.	Yassin A, Ghzawi A, Al-Mistarehi AH, El-Salem K, A YB, A MS, BenhadjDahman N,
326		AlAdamat N, Jemel A, Negida A, et al. Mortality rate and biomarker expression within
327		COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-
328		analysis. Future Sci OA. 2021;7:Fso713. doi: 10.2144/fsoa-2021-0036
329	18.	Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
330		impairment on COVID-19: a systematic review and meta-analysis. Crit Care.
331		2020;24:356. doi: 10.1186/s13054-020-03065-4
332	19.	Strambo D, Marto JP, Ntaios G, Nguyen TN, Michel P. Effect of Asymptomatic and
333		Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes. Stroke.
334		2024;55:78-88. doi: 10.1161/strokeaha.123.043899
335	20.	Kvernland A, Kumar A, Yaghi S, Raz E, Frontera J, Lewis A, Czeisler B, Kahn DE,
336		Zhou T, Ishida K, et al. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2
337		Patients Treated at a New York Healthcare System. Neurocrit Care. 2021;34:748-759.

doi: 10.1007/s12028-020-01077-0

339	21.	Wu B, Zhou JH, Wang WX, Yang HL, Xia M, Zhang BH, She ZG, Li HL. Association
340		Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in
341		Hospitalized Patients. Chin Med Sci J. 2021;36:17-26. doi: 10.24920/003866
342	22.	Wang H, Tang X, Fan H, Luo Y, Song Y, Xu Y, Chen Y. Potential mechanisms of
343		hemorrhagic stroke in elderly COVID-19 patients. Aging (Albany NY). 2020;12:10022-
344		10034. doi: 10.18632/aging.103335
345	23.	Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ,
346		Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated
347		intracerebral hemorrhage. Neurology. 2007;68:116-121. doi:
348		10.1212/01.wnl.0000250340.05202.8b
349	24.	Shahjouei S, Tsivgoulis G, Farahmand G, Koza E, Mowla A, Vafaei Sadr A, Kia A,
350		Vaghefi Far A, Mondello S, Cernigliaro A, et al. SARS-CoV-2 and Stroke
351		Characteristics: A Report From the Multinational COVID-19 Stroke Study Group.
352		Stroke. 2021;52:e117-e130. doi: 10.1161/strokeaha.120.032927
353	25.	Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, Lewis A, Melmed K,
354		Hochman K, Horwitz L, et al. Hemorrhagic stroke and anticoagulation in COVID-19. J
355		Stroke Cerebrovasc Dis. 2020;29:104984. doi:
356		10.1016/j.jstrokecerebrovasdis.2020.104984
357		
358		
359		

Variables	All Patients (N=603)	COVID & Stroke (N=66)	Stroke Only (N=537)	p values
Mean Age (SD)	64.40 (17.90)	62.11 (14.97)	64.68 (18.22)	0.270
Race				< 0.001
Native American	4 (0.7%)	0 (0.0%)	4 (0.7%)	
Asian or Pacific Islander	24 (4.0%)	5 (7.6%)	19 (3.5%)	
Black, Non-Hispanic	98 (16.3%)	4 (6.1%)	94 (17.5%)	
Hispanic	88 (14.6%)	27 (40.9%)	61 (11.4%)	
White, Non-Hispanic	290 (48.1%)	26 (39.4%)	264 (49.2%)	
Unknown/Other	99 (16.4%)	4 (6.1%)	95 (17.7%)	
Sex				0.200
Female	240 (39.8%)	25 (37.9%)	215 (40.0%)	
Male	282 (46.8%)	41 (62.1%)	241 (44.9%)	
Unknown/Other	81 (13.4%)	0 (0.0%)	81 (15.1%)	
Comorbidities				
Diabetes Mellitus	182 (30.2%)	37 (56.1%)	145 (27.0%)	< 0.001
Coronary Artery Disease	66 (10.9%)	6 (9.1%)	60 (11.2%)	0.762
Congestive Heart Failure	43 (7.1%)	7 (10.6%)	36 (6.7%)	0.363
History of Stroke	112 (18.6%)	11 (16.7%)	101 (18.8%)	0.799
Transient Ischemic Attack	25 (4.1%)	6 (9.1%)	19 (3.5%)	0.071
Hyperlipidemia	184 (30.5%)	24 (36.4%)	160 (29.8%)	0.341
Hypertension	371 (61.5%)	45 (68.2%)	326 (60.7%)	0.297
Atrial Fibrillation	57 (9.5%)	5 (7.6%)	52 (9.7%)	0.742
Chronic Kidney Disease	37 (6.1%)	13 (19.7%)	24 (4.5%)	< 0.001
Obesity (BMI > $30 \text{ kg/m}^2$ )	21 (3.5%)	3 (4.5%)	18 (3.4%)	0.886
Tobacco Use	130 (21.6%)	10 (15.2%)	120 (22.3%)	0.237
Stroke Type				0.331
Hemorrhagic	166 (27.5%)	22 (33.3%)	144 (26.8%)	
Ischemic	437 (72.5%)	44 (66.7%)	393 (73.2%)	
Death	118 (19.6%)	25 (37.9%)	93 (17.3%)	< 0.001

Table 1. Demographic characteristics, comorbidities, and outcomes for all patients presented

with stroke to a tertiary medical center between March 2020 and December 2020. COVID &

365 Stroke cohort included patients who were COVID-19 positive at the time of stroke presentation,

366 while Stroke Only cohort included patients who were COVID-19 negative. SD = standard

367 deviation. p values compared COVID & Stroke cohort and Stroke Only cohort.

Table 2. Demographic Characteristics, Comorbidities, and Outcomes for Patients with COVID-19 and Stroke				
Variables	COVID-First (N=45)	Stroke-First (N=21)	p values	
Mean Age (SD)	62.73 (12.51)	60.76 (19.52)	0.622	
Race			0.165	
Native American	0 (0.0%)	0 (0.0%)		
Asian or Pacific Islander	3 (6.7%)	2 (9.5%)		
Black, Non-Hispanic	2 (4.4%)	2 (9.5%)		
Hispanic	22 (48.9%)	5 (23.8%)		
White, Non-Hispanic	17 (37.8%)	9 (42.9%)		
Unknown/Other	1 (2.2%)	3 (14.3%)		
Sex			0.166	
Female	14 (31.1%)	11 (52.4%)		
Male	31 (68.9%)	10 (47.6%)		
Comorbidities				
Diabetes Mellitus	27 (60.0%)	10 (47.6%)	0.498	
Coronary Artery Disease	2 (4.4%)	4 (19.0%)	0.144	
Congestive Heart Failure	6 (13.3%)	1 (4.8%)	0.532	
History of Stroke	7 (15.6%)	4 (19.0%)	1.000	
Transient Ischemic Attack	3 (6.7%)	3 (14.3%)	0.587	
Hyperlipidemia	15 (33.3%)	9 (42.9%)	0.635	
Hypertension	29 (64.4%)	16 (76.2%)	0.503	
Atrial Fibrillation	3 (6.7%)	2 (9.5%)	1.000	
Chronic Kidney Disease	9 (20.0%)	4 (19.0%)	1.000	
Obesity (BMI > $30 \text{ kg/m}^2$ )	3 (6.7%)	0 (0.0%)	0.564	
Tobacco Use	8 (17.8%)	2 (9.5%)	0.615	
Days Between COVID and Stroke	19.30 (16.73)	1.00 (1.76)		
Stroke Type			0.400	
Hemorrhagic	17 (37.8%)	5 (23.8%)		
Ischemic	28 (62.2%)	16 (76.2%)		
Outcomes		. ,		
Acute Renal Failure	22 (48.9%)	4 (19.0%)	0.021	
Ventilation	27 (60.0%)	6 (28.6%)	0.017	
Tracheostomy	5 (11.1%)	0 (0.0%)	0.112	
ECMO	4 (8.9%)	0 (0.0%)	0.159	
Myocardial infarction	5 (11.1%)	0 (0.0%)	0.112	

18 (40.0%)

Death

0.804

7 (33.3%)

369 Table 2. Demographic characteristics, comorbidities, and outcomes for patients who were

370 COVID-19 positive when presented with stroke to a tertiary medical center between March 2020

and December 2020. COVID-first group included patients who were diagnosed with COVID-19

372 prior to stroke presentation, while Stroke-first group included patients who were diagnosed with

373 COVID-19 after stroke presentation. SD = standard deviation.

374

Table 3. Causes of Death by Systems in the COVID & Stroke Cohort				
	<b>COVID-First</b>	Stroke-First	Total	
Pulmonary	7	2	9	
Neurological	7	4	11	
Multi-organs	3	0	3	
Unknown	1	1	2	

Table 3. Causes of death by system in patients who were COVID-19 positive at the time of

376 stroke presentation.

377

Table 4. Stroke Types and Mortality for Patients Received Heparin or Not Prior toStroke Onset				
	<b>Received Heparin</b>	Did not Receive Heparin	p values	
Total	29	16		
Stroke Type			0.321	
Hemorrhagic	13 (44%)	4 (25%)		
Ischemic	16 (55.2%)	12 (75%)		
Death	12 (41.4%)	6 (37.5)	1.000	

Table 4. Stroke types and mortality for patients presented diagnosed with COVID-19 prior to

stroke presentation to a tertiary medical center between March 2020 and December 2020,

380 stratified by whether received heparin or not prior to stroke onset.

381

# 383 Supplemental Materials

# **Tables S1-S2**